SPI
LGND icon

Santori & Peters Inc’s Ligand Pharmaceuticals LGND Stock Holding History

Santori & Peters Inc’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-59
Closed -$5K – 315
2017
Q4 		$5K Buy
+59
New +$5.11K ﹤0.01% 437

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Santori & Peters Inc's LGND Position: Q1 2018 in Review

Santori & Peters Inc sold out of Ligand Pharmaceuticals (LGND) in Q1 2018, closing a stake of 59 shares — an estimated $5K sold.

Santori & Peters Inc first reported a position in LGND in Q4 2017 and held it in 1 quarter. The position peaked at $5K in Q4 2017. 326 funds tracked by Wall St. Rank hold LGND as of Q1 2018.

  • Santori & Peters Inc reported no remaining Ligand Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Santori & Peters Inc sold 59 Ligand Pharmaceuticals shares in Q1 2018, an estimated $5K.
  • Santori & Peters Inc first reported a position in Ligand Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Santori & Peters Inc's Ligand Pharmaceuticals position peaked at $5K in Q4 2017.
  • 326 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2018.

Based on Santori & Peters Inc's 13F filing for Q1 2018, filed 16 Apr 2018.